Jaypirca

Generic name: Pirtobrutinib

Drug class: BTK inhibitors

Dosage form: Tablets

Root of administration: Oral

Dose:50, 100 mg

Mechanism of action: Jaypirca belongs to the class of drugs called Bruton’s tyrosine kinase (BTK) inhibitors. BTK is a molecular target found across numerous B-cell leukemias and lymphomas including mantle cell lymphoma. Jaypirca works by binding to BTK to inhibit the activity of BTK kinase. This blocks the activity that leads to growth of the B-cells and causes cell death of the malignant B-cells.

Drug usage cases: Jaypirca is a prescription medicine used to treat adults with mantle cell lymphoma (MCL). Jaypirca is used to treat adults with mantle cell lymphoma (MCL) that has come back (relapsed) or did not respond to previous treatment (refractory), and who have already received two or more treatments for their cancer, including a covalent Bruton tyrosine kinase (BTK) inhibitor medicine.

Drug contra indications: Before you start treatment, tell your healthcare provider about all of your medical conditions, including if you:

have an infection or have been advised that you are at increased risk of infection have had recent surgery or plan to have surgery. Your healthcare provider may stop treatment for any planned medical, surgical, or dental procedure. have bleeding problems or are taking a blood thinner medicine, have or had heart rhythm problems, have high blood pressure, have a history of other cancers including skin cancer, have kidney problems.

Side effects: Jaypirca can cause serious side effects, including: Infections can happen during treatment with Jaypirca. These infections can be serious and may lead to death. Your healthcare provider may prescribe certain medicines if you have an increased risk of getting infections. Tell your healthcare provider right away if you develop fever, chills, weakness, flu-like symptoms, or any other signs of infection during treatment. Bleeding problems (hemorrhage) can happen during treatment with Jaypirca and can be serious and may lead to death. Your risk of severe bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you develop any signs or symptoms of bleeding, including:

blood in your stools or black stools (looks like tar), pink or brown urine, unexpected bleeding, or bleeding that is severe or you cannot control, vomit blood or vomit blood that looks like coffee grinds, cough up blood or blood clots, increased bruising, dizziness, weakness, confusion, changes in your speech, headache that lasts a long time, Decrease in blood cell counts. Decrease in blood cell counts (white blood cells, platelets, and red blood cells) are common with Jaypirca, but can also be severe. This may increase your risk of infection, bleeding, and anemia. Your healthcare provider should do blood tests to check your blood counts regularly during treatment. Heart rhythm problems (atrial fibrillation and atrial flutter) have happened in people treated with Jaypirca. Your risk for heart rhythm problems may be increased if you have high blood pressure or have had heart rhythm problems in the past. Tell your healthcare provider if you develop any of the following signs or symptoms:

fast or irregular heartbeat (palpitations), dizziness, fainting, chest discomfort, shortness of breath,

Second primary cancers. New cancers have happened in people during treatment with Jaypirca, including cancers of the skin or other organs. Your healthcare provider will check you for other cancers during treatment. Use sun protection when you are outside in sunlight.

Warnings: Serious and deadly infections caused by bacteria, viruses, or fungi have occurred with Jaypirca, 24% were Grade 3 or higher; opportunistic infections such as those caused by Pneumocystis jirovecci pneumonia also occurred. Consider prophylaxis, such as vaccinations and antibiotics in those at increased risk. Serious and fatal bleeding events (hemorrhage) have also occurred with Jaypirca. Monitor for any signs of bleeding and manage appropriately. Cytopenias, such as low neutrophils, platelets, or red blood cells can occur. Your healthcare provider will monitor your blood counts regularly throughout treatment. Cardiac arrhythmia including atrial fibrillation and atrial flutter and second primary cancers, including skin cancers, have also occurred.  Use sun protection when outside. Can cause fetal harm. Females of reproductive potential should use effective contraception. It is not known if this medicine is safe and effective in children.

Use during pregnancy or breastfeeding: are pregnant or plan to become pregnant. Jaypirca can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider will do a pregnancy test before starting treatment. You should use effective birth control (contraception) during treatment, and for 1 week after your last dose. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment. are breastfeeding or plan to breastfeed. It is not known if Jaypirca passes into your breast milk. Do not breastfeed during treatment, and for 1 week after your last dose.